Different susceptibility of B-type natriuretic Peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: The n-terminal part does matter

Clinical Chemistry

Volumn 62, Issue 4, 2016, Pages 617-622

  Semenov, Alexander G ^a   Katrukha, Alexey G ^a,b  

^a HyTest Ltd   (Finland)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; EPITOPE; MEMBRANE METALLOENDOPEPTIDASE; MONOCLONAL ANTIBODY; AMINOBUTYRIC ACID DERIVATIVE; PEPTIDE FRAGMENT; PRO-BNP1-108; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INCUBATION TIME; MASS SPECTROMETRY; NONHUMAN; PRECURSOR; PROTEIN DEGRADATION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; ESCHERICHIA COLI; GENETICS; GLYCOSYLATION; HEART FAILURE; LIMIT OF DETECTION; METABOLISM;

AMINOBUTYRATES; ANTIBODIES, MONOCLONAL; EPITOPES; ESCHERICHIA COLI; GLYCOSYLATION; HEART FAILURE; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PROTEOLYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TETRAZOLES;

EID: 84962433265     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.254524     Document Type: Article

References (33)

1. Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989;159:1427-34.
2. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010;56:1166-76.
3. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:2001-6.
4. Costello-Boerrigter LC, Lapp H, Boerrigter G, Lerman A, Bufe A, Macheret F, et al. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail 2013;1:207-12.
5. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73.
6. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
7. Pleister AP, Baliga RR, Haas GJ. Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux. Curr Heart Fail Rep 2011;8: 226-32.
8. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291(Pt 1):83-8.
9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993-1004.
10. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the prospective comparison of ARNI with ACEI to Determine Impact On Global Mortality And Morbidity In Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062-73.
11. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54-61.
12. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619-21.
13. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, et al. Direct immunochemiluminescent assay for proBNP and total BNPinhuman plasma proBNP and total BNP levels in normal and heart failure. PLoS One 2013;8:e53233.
14. Tamm NN, Seferian KR, Semenov AG, Mukharyamova KS, Koshkina EV, Krasnoselsky MI, et al. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clin Chem 2008;54:1511-8.
15. Humpel C. Organotypic vibrosections from whole brain adult Alzheimer mice (overexpressing amyloid-precursor-protein with the Swedish-Dutch-Iowa mutations) as a model to study clearance of beta-amyloid plaques. Frontiers Aging Neurosci 2015;7:47.
16. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulatingin human blood. Clin Chem 2008;54:866-73.
17. Katrukha AG, Bereznikova AV, Esakova TV, Pettersson K, Lovgren T, Severina ME, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997; 43:1379-85.
18. Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, Pecking AP. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005; 19:567-76.
19. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-7.
20. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
21. Kita T, Kida O, Kato J, Nakamura S, Eto T, Minamino N, et al. Natriuretic and hypotensive effects of brain natriuretic peptide (BNP) in spontaneously hypertensive rats. Life Sci 1989;44:1541-5.
22. Richards AM, McDonald D, Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J Clin Endocrinol Metab 1988;67:1134-9.
23. Pemberton CJ, Siriwardena M, Kleffmann T, Ruygrok P, Palmer SC, Yandle TG, Richards AM. First identification of circulating prepro-A-type natriuretic peptide (pre-proANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. Clin Chem 2012;58:757-67.
24. Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 1988;232:1-8.
25. Pankow K, Schwiebs A, Becker M, Siems WE, Krause G, Walther T. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 2009;393:496-503.
26. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239-46.
27. Walther T, Stepan H, Pankow K, Becker M, Schultheiss HP, Siems WE. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem 2004; 385:179-84.
28. Dickey DM, Potter LR. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase - A with reduced potency. Clin Chem 2011;57:1272-8.
29. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007;101:875-82.
30. Norman JA, Little D, Bolgar M, Di Donato G. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 1991;175:22-30.
31. Clerico A, Franzini M, Masotti S, Prontera C, Passino C. State of the art of immunoassay methods for B-type natriuretic peptides: an update. Crit Rev Clin Lab Sci 2015;52:56-69.
32. Tamm NN, Semenov AG, Seferian KR, Bereznikova A V, Murakami MM, Apple FS, et al. Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. Clin Biochem 2011;44:257-9.
33. Semenov AG, Seferian KR, Tamm NN, Artem'eva MM, Postnikov AB, Bereznikova AV, et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem 2011;57:883-90.